Scopus BioPharma (SCPS) Competitors $0.0003 0.00 (-25.00%) As of 09/8/2025 10:27 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock SCPS vs. NAVB, OBSV, SYRS, SMFL, VRPX, STAB, EVLO, CMRA, GNCAQ, and GNCAShould you be buying Scopus BioPharma stock or one of its competitors? The main competitors of Scopus BioPharma include Navidea Biopharmaceuticals (NAVB), ObsEva (OBSV), Syros Pharmaceuticals (SYRS), Smart for Life (SMFL), Virpax Pharmaceuticals (VRPX), Statera Biopharma (STAB), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), and Genocea Biosciences (GNCA). These companies are all part of the "pharmaceutical products" industry. Scopus BioPharma vs. Its Competitors Navidea Biopharmaceuticals ObsEva Syros Pharmaceuticals Smart for Life Virpax Pharmaceuticals Statera Biopharma Evelo Biosciences Comera Life Sciences Genocea Biosciences Genocea Biosciences Scopus BioPharma (NASDAQ:SCPS) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends. Is SCPS or NAVB more profitable? Company Net Margins Return on Equity Return on Assets Scopus BioPharmaN/A N/A N/A Navidea Biopharmaceuticals N/A N/A N/A Which has more risk & volatility, SCPS or NAVB? Scopus BioPharma has a beta of -0.16, indicating that its share price is 116% less volatile than the S&P 500. Comparatively, Navidea Biopharmaceuticals has a beta of 1.99, indicating that its share price is 99% more volatile than the S&P 500. Which has preferable earnings and valuation, SCPS or NAVB? Scopus BioPharma has higher earnings, but lower revenue than Navidea Biopharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioScopus BioPharmaN/AN/A-$11.61MN/AN/ANavidea Biopharmaceuticals$8.13K6.16-$15.18MN/AN/A Does the media prefer SCPS or NAVB? In the previous week, Scopus BioPharma's average media sentiment score of 0.00 beat Navidea Biopharmaceuticals' score of -0.80 indicating that Scopus BioPharma is being referred to more favorably in the media. Company Overall Sentiment Scopus BioPharma Neutral Navidea Biopharmaceuticals Negative Do insiders & institutionals believe in SCPS or NAVB? 0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 5.1% of Scopus BioPharma shares are held by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryNavidea Biopharmaceuticals beats Scopus BioPharma on 4 of the 6 factors compared between the two stocks. Get Scopus BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for SCPS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SCPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart SCPS vs. The Competition Export to ExcelMetricScopus BioPharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13K$871.92M$5.81B$9.97BDividend YieldN/A4.84%6.70%4.53%P/E RatioN/A1.1775.5526.10Price / SalesN/A26.96464.7386.45Price / CashN/A19.5625.7029.14Price / BookN/A6.7311.426.17Net Income-$11.61M-$4.20M$3.28B$269.83M7 Day PerformanceN/A1.45%0.80%3.13%1 Month PerformanceN/A9.10%10.73%8.29%1 Year PerformanceN/A27.88%58.92%25.34% Scopus BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCPSScopus BioPharmaN/A$0.00-25.0%N/A+0.0%$13KN/A0.009Gap DownNAVBNavidea BiopharmaceuticalsN/A$0.00flatN/A-50.0%$50K$8.13K0.0010High Trading VolumeOBSVObsEvaN/A$0.00flatN/AN/A$39KN/A0.0050SYRSSyros Pharmaceuticals3.9689 of 5 stars$0.00-50.0%$1.00+90,809.1%-99.9%$30K$386K0.00120Gap DownSMFLSmart for LifeN/A$0.00+22.7%N/A-99.6%$19K$11.11M0.00110Gap DownVRPXVirpax Pharmaceuticals0.0994 of 5 stars$0.01flatN/A-99.9%$14KN/A0.007STABStatera BiopharmaN/A$0.00+100.0%N/A-83.3%$11KN/A0.0020Gap UpHigh Trading VolumeEVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120CMRAComera Life SciencesN/A$0.00flatN/AN/A$6K$1.00M0.002GNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070 Related Companies and Tools Related Companies Navidea Biopharmaceuticals Competitors ObsEva Competitors Syros Pharmaceuticals Competitors Smart for Life Competitors Virpax Pharmaceuticals Competitors Statera Biopharma Competitors Evelo Biosciences Competitors Comera Life Sciences Competitors Genocea Biosciences Competitors Genocea Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SCPS) was last updated on 9/9/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredBuffett, Gates and Bezos Dumping StocksThe world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated b...Banyan Hill Publishing | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredWashington prepares for warWhile the headlines obsess over overseas conflicts, Washington has been quietly preparing for something much b...Porter & Company | SponsoredTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scopus BioPharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Scopus BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SCPS Stock Alerts